Verona Pharma is at an exciting stage of its development having announced unequivocally positive results from all of its clinical trials with a new proprietary suspension formulation of RPL554. Data from a Phase IIa combination trial is due in Q2 and we take the opportunity ahead of this to reiterate the significant upside potential of RPL554. As an illustration, our intrinsic value per share could increase from 9p to 35p if we assume RPL554 successfully enters the market (estimate 2021). We rem ....

21 Apr 2016
Significant potential upside

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Significant potential upside
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
21 Apr 2016 -
Author:
Singer CM Team -
Pages:
12 -
Verona Pharma is at an exciting stage of its development having announced unequivocally positive results from all of its clinical trials with a new proprietary suspension formulation of RPL554. Data from a Phase IIa combination trial is due in Q2 and we take the opportunity ahead of this to reiterate the significant upside potential of RPL554. As an illustration, our intrinsic value per share could increase from 9p to 35p if we assume RPL554 successfully enters the market (estimate 2021). We rem ....